ICML 2023 | BRUIN CLL-322 update: fixed-duration pirtobrutinib plus VR vs VR in patients with R/R CLL
Toby Eyre, MBChB (Hons), DipMedEd, MRCP (UK), FRCPath (UK), MD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, describes the ongoing global Phase III randomized BRUIN CLL-322 trial (NCT04965493). The trial will compare venetoclax plus rituximab (VR) to VR plus fixed-duration pirtobrutinib for patients with chronic lymphocytic leukemia (CLL) who have received prior therapy. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Roche: Education Honorarium, Advisory Board Honorarium, Travel to scientific conferences; Gilead: Honorarium; Research support; Travel to scientific conferences; KITE: Education Honorarium, Advisory Board Honorarium; Janssen: Honorarium; Abbvie: Honorarium; Travel to scientific conferences; AstraZeneca: Honorarium, Research funding, Travel to scientific conferences; Loxo Oncology: Advisory Board Honorarium, Trial steering committee; Beigene: Advisory Board Honorarium, Research funding; Incyte: Advisory Board Honorarium; Secura Bio: Advisory Board Honorarium; Autolus: Advisory Board Honorarium
